Brain Health & Nootropics
Selank
← Back to Library
Limited / unverified FDA safety flag Limited / unverified Neural Anxiolytic
Educational reference only. Read the full disclaimer.
The protocols below are not automatically an FDA-approved or clinically verified regimen unless
explicitly marked as label-verified or clinical-trial above.
Overview
Route(s): Subcutaneous
Typical vial sizes: 10, 30 mg
Dosing window: As Needed / Morning
Receptor / target: Enkephalinase
Properties: Not stated
Pre-mixed: No
Unverified protocol notes
Standard Protocol
| Timeframe | Dose | Notes |
|---|---|---|
| Weeks 1-4 | 250mcg to 500mcg daily | Administered in the morning to lower baseline anxiety, or as-needed for acute stress. |
Unverified protocol note; not label dosing unless graded otherwise on this page.
Alternative: Sleep Aid
| Timeframe | Dose | Notes |
|---|---|---|
| As Needed | 500mcg pre-bed | Helps calm a racing mind to facilitate sleep onset without acting as a direct sedative. |
Unverified alternative protocol; not an approved-label regimen unless graded otherwise on this page.
Protocol logic check
Protocol context: Nootropic protocols are state-dependent: sleep, anxiety, stimulants, psychiatric history, and route can change the response. The logic is morning-biased, low-entry dosing, and stopping if arousal or mood destabilizes. Entry context: target (Enkephalinase); route Subcutaneous; timing As Needed / Morning. Limited-evidence dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit.
Independent evidence
Independent safety notes: FDA lists selank acetate with immunogenicity/impurity concerns and insufficient human safety information.
Regulatory status: unapproved or compounded peptide with FDA safety risk flag
Storage
No independently verified storage guidance found. Treat any unverified storage claim as unverified, and see the general storage guidance in the FAQ.
Contraindications (limited evidence)
- Known hypersensitivity to Selank, tuftsin-derived peptides, or formulation excipients. Limited / unverified
- Concurrent use with opioid analgesics: Selank increases endogenous enkephalin tone via enkephalinase inhibition; in subjects already on opioid agonists, the additive mu/delta opioid receptor activity theoretically potentiates opioid effects and may complicate analgesic dosing. Limited / unverified
- Concurrent use with benzodiazepines or barbiturates: while Selank does not act on GABA-A receptors, overlapping CNS depressant effects in highly anxiolytic-saturated subjects may produce excessive sedation; use with caution. Limited / unverified
- Active severe depressive episode with psychomotor retardation: while Selank has mood-stabilizing properties, its primary anxiolytic action without stimulant properties could theoretically deepen motivational suppression in severely retarded depression; monitor carefully. Limited / unverified
- Pregnancy: no clinical safety data. Limited / unverified
- Breastfeeding: no safety data. Limited / unverified
- Pediatric use: not established. Limited / unverified
- Narcolepsy or hypersomnia: Selank's enkephalin-potentiating activity could worsen daytime sleepiness in subjects with pre-existing hypersomnia disorders. Limited / unverified
Side effects (limited evidence)
- Mild fatigue and sedation at high doses: the most commonly reported adverse effect; dose-dependent; occurs primarily at doses above 500mcg; characterized by a calm, slightly sleepy state that is usually welcome in evening use but problematic for daytime productivity at excessive doses. Limited / unverified
- Mild dizziness: uncommon; related to the brief cardiovascular effects of enkephalin potentiation. Limited / unverified
- Mild headache: uncommon; transient; reported in a small subset of users in the initial days of a cycle. Limited / unverified
- Reduced motivation in some subjects: enkephalin potentiation produces profound emotional calm that, in a minority of subjects, blunts goal-directed drive and ambition; resolve with dose reduction. Limited / unverified
- Emotional blunting at high doses: excessive enkephalin tone can produce emotional flatness; this is the upper-dose limit signal that warrants dose reduction. Limited / unverified
- Nasal irritation with intranasal formulations: mild; not applicable to subcutaneous administration. Limited / unverified
- No withdrawal syndrome: Selank has no physical dependence liability; cessation does not produce rebound anxiety, insomnia, or other withdrawal phenomena that characterize benzodiazepine discontinuation. Limited / unverified
- No cognitive impairment: unlike benzodiazepines, Selank does not impair memory formation, reaction time, or processing speed at anxiolytic doses; the opposite is typically observed. Limited / unverified
- No respiratory depression: GABA-independent mechanism means Selank carries no overdose risk from respiratory suppression. Limited / unverified
Compatibility
The relationships below come from the source site's internal engine and were not verified independently. Treat them as a starting point for a conversation with a clinician. They carry no safety guarantee.
Reported synergistic:
Reported contraindicated combinations:
None listed.